These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 22888990)

  • 1. Arthroscopic synovectomy of the elbow covered with rFVIIa in a haemophilia B juvenile with inhibitor.
    Shimada K; Takedani H; Inoue K; Yamasaki K
    Haemophilia; 2012 Nov; 18(6):e414-6. PubMed ID: 22888990
    [No Abstract]   [Full Text] [Related]  

  • 2. Surgical experience with rFVIIa (NovoSeven) in congenital haemophilia A and B patients with inhibitors to factors VIII or IX.
    Valentino LA; Cooper DL; Goldstein B
    Haemophilia; 2011 Jul; 17(4):579-89. PubMed ID: 21294815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Major orthopaedic surgeries for haemophilia with inhibitors using rFVIIa.
    Takedani H; Kawahara H; Kajiwara M
    Haemophilia; 2010 Mar; 16(2):290-5. PubMed ID: 19925628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A rare case of an acquired inhibitor to factor IX.
    Krishnamurthy P; Hawche C; Evans G; Winter M
    Haemophilia; 2011 Jul; 17(4):712-3. PubMed ID: 21371188
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors: overall rFVIIa exposure and intervals following high (>240 μg kg⁻¹) rFVIIa doses across clinical trials and registries.
    Shapiro AD; Neufeld EJ; Blanchette V; Salaj P; Gut RZ; Cooper DL
    Haemophilia; 2014 Jan; 20(1):e23-31. PubMed ID: 24354484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors.
    Abshire T; Kenet G
    Haemophilia; 2008 Sep; 14(5):898-902. PubMed ID: 18684126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal thromboembolism during treatment with recombinant activated factor VII (rFVIIa) in a child with hemophilia B with factor IX inhibitors.
    Milošević D; Bilić E; Batinić D; Poropat M; Štern-Padovan R; Galić S; Turudić D
    BMC Pediatr; 2014 Dec; 14():315. PubMed ID: 25515020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence-based use of recombinant FVIIa (NovoSeven, NiaStase) for the treatment of hemophilia with inhibitors in children and adolescents.
    Goldstein B; Geldziler B; Bjerre J; Seremetis S
    Transfus Apher Sci; 2008 Feb; 38(1):25-32. PubMed ID: 18267372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elective orthopaedic surgery for haemophilia patients with inhibitors: single centre experience of 40 procedures and review of the literature.
    Caviglia H; Candela M; Galatro G; Neme D; Moretti N; Bianco RP
    Haemophilia; 2011 Nov; 17(6):910-9. PubMed ID: 21342367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exposure and safety of higher doses of recombinant factor VIIa ≥250 μg kg(-1) in individuals with congenital haemophilia complicated by alloantibody inhibitors: the Haemophilia and Thrombosis Research Society Registry experience (2004-2008).
    Neufeld EJ; Kessler CM; Gill JC; Wilke CT; Cooper DL;
    Haemophilia; 2011 Jul; 17(4):650-6. PubMed ID: 21299750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.
    Hedner U
    Thromb Haemost; 1999 Aug; 82(2):531-9. PubMed ID: 10605747
    [No Abstract]   [Full Text] [Related]  

  • 12. Successful eradication of inhibitor in a patient with severe haemophilia B and anaphylaxis to factor IX concentrates: is there a role for Rituximab and desensitization therapy?
    Gamerman S; Singh AM; Makhija M; Sharathkumar A
    Haemophilia; 2013 Nov; 19(6):e382-5. PubMed ID: 23992223
    [No Abstract]   [Full Text] [Related]  

  • 13. Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors.
    Gringeri A; Fischer K; Karafoulidou A; Klamroth R; López-Fernández MF; Mancuso E;
    Haemophilia; 2011 Jul; 17(4):630-5. PubMed ID: 21323801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lupus anticoagulants associated inhibitor against factor IX in a young patient with haemophilia B.
    Barnbrock A; Heller C; Königs C; Budde U; Schwabe D
    Haemophilia; 2016 Sep; 22(5):e437-9. PubMed ID: 27353656
    [No Abstract]   [Full Text] [Related]  

  • 15. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization.
    Collins PW; Chalmers E; Hart DP; Liesner R; Rangarajan S; Talks K; Williams M; Hay CR;
    Br J Haematol; 2013 Jan; 160(2):153-70. PubMed ID: 23157203
    [No Abstract]   [Full Text] [Related]  

  • 16. Eradication of factor IX neutralizing and anaphylactic inhibitors in a patient with severe haemophilia B using cyclophosphamide immune suppression and factor IX desensitization.
    Greenmyer JR; Grindeland CJ; Kobrinsky NL
    Haemophilia; 2020 Mar; 26(2):e51-e54. PubMed ID: 31961035
    [No Abstract]   [Full Text] [Related]  

  • 17. Prolonged recombinant activated factor VII (rFVIIa) treatment for severe bleeding in a factor-IX-deficient patient with an inhibitor.
    Schmidt ML; Smith HE; Gamerman S; DiMichele D; Glazer S; Scott JP
    Br J Haematol; 1991 Jul; 78(3):460-3. PubMed ID: 1873233
    [No Abstract]   [Full Text] [Related]  

  • 18. Haemostatic efficacy and safety of bolus and continuous infusion of recombinant factor VIIa are comparable in haemophilia patients with inhibitors undergoing major surgery. Results from an open-label, randomized, multicenter trial.
    Pruthi RK; Mathew P; Valentino LA; Sumner MJ; Seremetis S; Hoots WK;
    Thromb Haemost; 2007 Oct; 98(4):726-32. PubMed ID: 17938794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Relevance of a single dose of 270 microg/kg recombinant factor VIIa for the treatment of patients with haemophilia and inhibitors - Recommendations from the GTH experts].
    Auerswald G; Muntean W; Kemkes-Matthes B; Klamroth R; Krause M; Kurnik K; Oldenburg J; Pabinger-Fasching I; Schramm W; Zimmermann R; Zotz RB
    Hamostaseologie; 2009 May; 29(2):197-203. PubMed ID: 19404511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High dose factor VIIa improves clot structure and stability in a model of haemophilia B.
    Wolberg AS; Allen GA; Monroe DM; Hedner U; Roberts HR; Hoffman M
    Br J Haematol; 2005 Dec; 131(5):645-55. PubMed ID: 16351642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.